France Biotech publishes 3rd edition of its review of product development pipelines in French life science companies
In 2008, the number of drugs and medical devices in late-stage development rose markedly, thanks to significant levels of investment over the period 2005-2007
France Biotech has published the 3rd edition of its annual Drug Pipeline Review. The survey was part-funded by the French Ministry of the Economy, Industry & Finance.
The study summarizes and analyses data collected in 2008 on 227 healthcare products under development, including 158 drugs (at 51 life science companies), 41 in vitro diagnostics (at 22 companies) and 28 medical devices (at 17 companies). This year’s review included in vitro diagnostics and medical devices for the first time. In all, 85 French life science SMEs developing healthcare products participated in the survey. Most were incorporated fairly recently - 45% in the last 5 years, half of which are developing drugs.
"The dynamic growth of France’s life science industry - as revealed by the increasing number of very innovative products in the pipeline - may well slacken off. In fact, with a 79% drop in investment in 2008, our innovative SMEs are going to have trouble funding all their drug development programs because the latter are very resource-intensive! To help our innovative SMEs generate jobs and economic growth and become tomorrow’s business champions, France Biotech has asked the French government (on February 5) to implement a stimulus plan based on innovation", commented Philippe Pouletty MD, Chairman of France Biotech.
Other news from the department business & finance
